21 CFR Part 111 for Canadian NHP Exporters: A Compliance Guide

Many Canadian natural health product (NHP) companies assume that a Health Canada product licence and a site licence are enough to sell the same product in the United States. They are not. The United States does not recognise the Natural Health Products Regulations. It treats the same bottle as a dietary supplement, governed by a different law and a different set of manufacturing rules known as 21 CFR Part 111.

For a Canadian brand, that gap is where deals stall, shipments get detained and warning letters begin. Through 2026, FDA has stepped up current Good Manufacturing Practice enforcement against dietary supplement makers, and a single inspection now routinely produces a warning letter that cites failures across hygiene, equipment, specifications, records and complaint handling at once. This guide explains what Part 111 requires, why your Canadian approvals do not carry across the border, what recent enforcement shows, and the practical steps to get an NHP export ready for the US market with confidence.

Executive summary

Canada and the United States run two separate systems for what Canadians call natural health products. In Canada, these products carry an NPN or DIN-HM and are made under Good Manufacturing Practices set out in GUI-0158. In the United States, the identical product is a dietary supplement under the Dietary Supplement Health and Education Act of 1994 (DSHEA), and it must be manufactured in line with 21 CFR Part 111. Neither approval substitutes for the other. A Canadian exporter that wants US shelf space needs to build Part 111 compliance on top of its Canadian file, register the manufacturing site with FDA, appoint a US Agent, verify ingredient identity by testing, handle any new dietary ingredient notification, and support the US importer's own verification duties. A rising wave of 2026 FDA warning letters shows where firms actually get caught. The rest of this article works through each obligation and the mistakes that most often trip up first time exporters.

What is 21 CFR Part 111?

What it is. 21 CFR Part 111 is the US Food and Drug Administration's current Good Manufacturing Practice (cGMP) rule for manufacturing, packaging, labelling or holding dietary supplements. It was finalised on 25 June 2007 and applies to any facility that performs those activities for a supplement sold in the United States, including facilities located in Canada.

Why it matters. Part 111 is the standard FDA inspectors measure you against. A supplement made outside these controls is considered adulterated under US law, which exposes it to import detention, refusal, recall and warning letters. For a Canadian brand, non-compliance is not a paperwork problem, it is a market access problem.

What to do. Treat Part 111 as a separate quality system project, not a translation of your Canadian file. Map your existing GUI-0158 quality management system against Part 111 subparts, close the gaps, and document everything in the master manufacturing record that Part 111 requires for each product and batch size.

Why your Health Canada NPN and site licence do not carry over

What it is. A Health Canada product licence (NPN) authorises sale in Canada and confirms that the product's safety, efficacy and quality were assessed under the Natural Health Products Regulations. A Canadian site licence confirms the site meets GUI-0158 GMP. These are Canadian authorisations with Canadian legal force only.

Why it matters. The United States does not have an NHP category. Under DSHEA, your product is a food, specifically a dietary supplement, and it is not pre-approved by FDA at all. There is no US equivalent of an NPN to apply for. Instead, the burden sits on the manufacturer and distributor to make sure the product is safe, properly made under Part 111 and correctly labelled before it goes to market. The US system swaps pre-market approval for continuous manufacturer responsibility.

What to do. Do not market or label a US bound product with Canadian claims, the NPN, or Canadian risk statements. Rebuild the label to US rules, confirm your manufacturing meets Part 111, and keep the two regulatory files clearly separate. If you are still deciding which Canadian licence pathway fits your product in the first place, our guide comparing an NHP licence and a cannabis licence sets out how Health Canada classifies borderline products.

The table below summarises the core differences a Canadian exporter needs to plan around.

Feature	Canada (NHP Regulations)	United States (DSHEA and 21 CFR Part 111)
Product category	Natural health product	Dietary supplement (a category of food)
Pre-market approval	Yes, product licence (NPN) required before sale	No pre-market approval of the product itself
GMP standard	GUI-0158 (NHP GMP)	21 CFR Part 111
Site authorisation	Site licence issued by Health Canada	Facility registration with FDA plus a US Agent
New ingredient route	Product licence application assessment	New Dietary Ingredient (NDI) notification, 75 days before marketing
Health claims	Approved claims tied to the NPN	Structure or function claims with the mandatory DSHEA disclaimer

The 2026 enforcement wave: what recent Part 111 warning letters show

What it is. Through 2026, FDA has increased cGMP enforcement against dietary supplement makers, and a single inspection now routinely produces a warning letter that cites failures across hygiene, the physical plant, equipment, finished product specifications, records and complaint handling at the same time.

Why it matters. These are the exact controls a Canadian exporter has to demonstrate to sell in the United States. A facility that passes a Health Canada NHP inspection can still fail Part 111 on the specification, record keeping and complaint requirements that GUI-0158 words differently or in less detail.

What to do. Read recent warning letters as a checklist of where firms actually get caught, and pressure test your own system against the same clauses before an importer or FDA does.

In a warning letter dated 4 June 2026, FDA cited a New York dietary supplement manufacturer, Nutratech, LLC, following an inspection of its facility from 22 September to 15 October 2025. The letter listed seven cGMP violations and one labelling violation. The pattern is instructive, because none of the findings were exotic. They were the everyday controls that a mature quality system is supposed to run without thinking.

The table below maps the Nutratech findings to the Part 111 clause and to what each one means for your own system.

21 CFR clause	What FDA cited	What it means for your system
111.10(b)	Hygienic practices not followed, and an ill employee kept working	Enforce and record gowning, hand and arm hygiene, and a fitness for work policy
111.15(b)	Physical plant not clean or in repair	Execute and verify master sanitation schedules, do not just write them
111.27(a)	Equipment not suitable, cleanable or maintained	Use food grade, cleanable equipment and record cleaning and maintenance
111.70(e)	No finished batch specifications for identity, purity, strength and composition	Organoleptic checks alone cannot identify ingredients; set numerical specs and test methods
111.210	Master manufacturing records missing required information	The MMR must state the control points and verification steps for each product
111.260	Batch production records missing required information	Record equipment used, cleaning, actual yield and monitoring results for every batch
111.553 and 111.560(a)	Complaint procedures not followed or documented	Investigate and record every product complaint; the complaint file is a common inspection ask
Section 403(w) of the Act	An undeclared major food allergen on a label	Rebuild the US label with correct allergen declarations

The most important lesson for a Canadian exporter is that FDA was not persuaded by the firm's corrective action reports alone. The letter repeatedly notes that the company described corrective actions but did not submit the evidence, such as cleaning logs, photos, training records and completed complaint investigations. In a Part 111 world, an undocumented correction is treated as no correction. This is the same discipline we describe in our work on root cause investigations that survive an inspection and on audit trail review and data integrity. The finished batch specification finding also reinforces the identity testing point in the next section: an organoleptic check is not an identity test.

FDA facility registration and the US Agent requirement

What it is. Under the Food Safety Modernization Act, any facility that manufactures, processes, packs or holds food, including dietary supplements, for the US market must register with FDA. A facility outside the United States must also designate a US Agent, a person or business physically in the United States who serves as FDA's point of contact.

Why it matters. Without an active registration and a US Agent, your facility cannot lawfully ship supplements into the United States, and FDA will not process import lines tied to it. Registration is also how FDA finds you for inspection. The trade agreement between Canada, the US and Mexico does not waive this requirement.

What to do. Register the manufacturing facility, appoint a reliable US Agent, and keep the registration current. Food facility registrations must be renewed in every even-numbered year, during the window that runs from 1 October to 31 December. Because 2026 is an even year, the renewal window opens on 1 October 2026. Missing it makes the registration expire and can halt shipments.

Specifications and identity testing under 111.70 and 111.75

What it is. Part 111 requires you to set written specifications for identity, purity, strength and composition, and for contamination limits, at the component, in-process, finished-batch, packaging and labelling stages. Section 111.70 tells you which specifications to establish, and section 111.75 tells you how to determine whether they are met.

Why it matters. This is the single most common Part 111 failure in FDA warning letters, and the Nutratech letter is a fresh example: FDA rejected organoleptic identity checks as insufficient and cited a failure to set finished batch specifications under 111.70(e). Section 111.75(a)(1)(i) requires at least one appropriate test to verify the identity of every component that is a dietary ingredient. For that identity test, you cannot simply rely on a supplier's certificate of analysis. A certificate can be used for other component specifications, but only if you have first qualified the supplier, confirmed the certificate's reliability, and set up periodic re-confirmation. Skipping identity testing is treated as a core cGMP breach.

What to do. Establish scientifically valid identity test methods for each dietary ingredient, and verify finished batches against your product specifications using a sound sampling plan. Build a supplier qualification file for any certificate you intend to rely on for other specifications. If you lack in-house analytical capacity, our quality control and analytical coordination services can help you select methods and qualify testing laboratories.

Stage	Part 111 expectation	Can a supplier CoA be used?
Identity of a dietary ingredient	At least one appropriate identity test (111.75(a)(1)(i))	No. You must test, unless FDA grants a petition
Other component specifications	Test, or rely on a qualified supplier CoA (111.75(a)(2))	Yes, if the supplier is qualified and re-confirmed
Finished batch	Verify identity, purity, strength, composition and contaminant limits	Testing on a statistical subset or every batch
Packaging and labels	Visual identification and review of supplier documents	Visual check plus invoice or certification review

New Dietary Ingredient notifications and claims

What it is. A New Dietary Ingredient (NDI) is a dietary ingredient that was not marketed in the United States in a supplement before 15 October 1994. If your product contains one, you generally must submit an NDI notification to FDA at least 75 days before marketing, setting out the basis for concluding the ingredient is reasonably expected to be safe.

Why it matters. An ingredient that is well accepted in Canada may still be an NDI in the United States. Marketing a supplement that contains an NDI without the required notification renders the product adulterated. Separately, any structure or function claim, for example that an ingredient supports immune health, must carry the DSHEA disclaimer that the statement has not been evaluated by FDA and the product is not intended to diagnose, treat, cure or prevent any disease, and you must notify FDA of the claim within 30 days of first marketing.

What to do. Screen each ingredient against US market history before you export. Where an NDI notification is needed, budget for the safety dossier and the 75 day clock. Review every claim on the US label so it stays within permitted structure or function language and carries the disclaimer.

FSVP: the US importer's parallel obligation

What it is. The Foreign Supplier Verification Program (FSVP) requires the US importer of record to verify that a foreign supplier produces food, including supplements, to a US equivalent standard. The Canadian Food Inspection Agency summarises FSVP expectations for exporters. For dietary supplements, FSVP requirements are tailored so that they line up with Part 111 controls.

Why it matters. Even though FSVP sits with the importer, a Canadian exporter that cannot supply the records an importer needs will lose the account. Importers routinely ask for your Part 111 quality documentation, specifications, test results and corrective action history. If you cannot produce them, you are hard to buy from.

What to do. Prepare a supplier information pack that gives importers what FSVP asks for, and keep it current. Our article on FDA supplier oversight and contract manufacturer accountability explains what US buyers expect from their foreign partners.

Part 111 export-readiness checklist

Use this checklist to test whether a Canadian NHP is genuinely ready for the US market.

Manufacturing facility registered with FDA, with renewal scheduled for the 2026 even-year window.
US Agent appointed, with a written agreement and clear responsibilities.
Written specifications set for components, in-process points, finished batches, packaging and labels.
Finished batch product specifications set with numerical limits and validated test methods, not organoleptic checks alone (111.70(e)).
Identity of every dietary ingredient verified by an appropriate, scientifically valid test.
Supplier qualification file in place for any certificate of analysis relied on for other specifications.
Master manufacturing record and batch production records maintained for each product and batch size, with the elements 111.210 and 111.260 require.
Written, followed and documented product complaint procedure, with recorded investigations (111.553 and 111.560).
Each ingredient screened for NDI status, with notifications filed where required.
US label rebuilt with a Supplement Facts panel, permitted claims, the DSHEA disclaimer and correct allergen declarations.
Supplier information pack ready to support the importer's FSVP obligations.

Common mistakes Canadian exporters make

Assuming the NPN and Canadian site licence satisfy FDA. They do not, and the US has no product to approve in the first place.
Relying on a supplier certificate of analysis for dietary ingredient identity. Section 111.75 requires you to test.
Using organoleptic checks as identity specifications, which FDA has rejected as insufficient.
Describing corrective actions in a 483 response without submitting the evidence FDA asks for, so the correction is treated as incomplete.
Letting the FDA registration lapse by missing the even-year renewal window.
Shipping an ingredient that is an NDI in the United States without filing the 75 day notification.
Carrying Canadian claims or the NPN onto the US label instead of using compliant structure or function language with the disclaimer.
Leaving the importer to satisfy FSVP alone, then losing the account when records cannot be produced.

Frequently asked questions

Does my Health Canada site licence count toward FDA compliance?

No. A Health Canada site licence confirms compliance with GUI-0158, the Canadian NHP GMP. FDA assesses your facility against 21 CFR Part 111. The two standards overlap in principle but are audited separately, so you need to demonstrate Part 111 compliance on its own terms, including FDA facility registration and a US Agent.

Is FDA enforcement against supplements really increasing?

FDA has been active on dietary supplement cGMP through 2026, and recent warning letters, such as the June 2026 letter to Nutratech, LLC, show inspections producing multiple simultaneous findings across hygiene, equipment, specifications, records and complaint handling. The practical takeaway is that a single inspection can surface many issues at once, so a Canadian exporter should treat the full Part 111 system, not just identity testing, as inspection ready.

Do I need to test every dietary ingredient for identity?

Yes. Section 111.75(a)(1)(i) requires at least one appropriate test to verify the identity of each component that is a dietary ingredient, unless FDA grants a petition for alternative testing. A supplier certificate of analysis is not enough for the identity of a dietary ingredient, although it can support other component specifications if the supplier is properly qualified. Organoleptic checks alone do not satisfy the requirement.

What is a US Agent and do I have to have one?

A US Agent is a person or company located in the United States who acts as FDA's contact for your foreign facility. A facility outside the United States must designate a US Agent before it can complete FDA registration. The agent handles communications and can receive information on your behalf, so choose one that is responsive and understands your product.

When is the next FDA registration renewal?

Food facility registrations, including those for dietary supplement facilities, must be renewed in every even-numbered year between 1 October and 31 December. The next window falls in 2026. Diarise it early, because a lapsed registration can stop your US shipments.

Can I use my Canadian label in the United States?

No. US supplements need a Supplement Facts panel, US format ingredient and allergen information, and any structure or function claim must carry the DSHEA disclaimer. The NPN and Canadian claim wording should not appear on the US label. Plan a separate US label from the start, and confirm every major food allergen is declared, because an undeclared allergen misbrands the product.

Who is responsible for FSVP, me or my US buyer?

The US importer of record holds the FSVP obligation. In practice, though, they rely on you for the documentation that verification depends on, such as your specifications, test results and corrective action records. Being ready to supply that pack makes you an easier supplier to keep.

How MFLRC can help

MF License and Regulatory Consultants helps Canadian NHP companies cross into the US supplement market without surprises. We run a Part 111 gap assessment against your existing GUI-0158 system, write or upgrade the SOPs and master manufacturing records Part 111 expects, and set up identity testing, finished batch specifications and complaint handling that hold up under FDA scrutiny. Our regulatory affairs, licensing and import/export team manages FDA facility registration, US Agent coordination and NDI screening, while our audit services prepare you for inspection and for the questions US importers will ask under FSVP.

Whether you are shipping your first pallet south or cleaning up after a detention, we can map the pathway and do the technical work with you.

Book a US market-entry consultation

Conclusion

The distance between a Canadian NHP and a US supplement is not a translation, it is a second compliance system. Part 111 sets the manufacturing bar, FDA registration and a US Agent get you through the door, identity testing and finished batch specifications keep you there, and FSVP keeps your importer comfortable. The 2026 enforcement wave is a reminder that inspectors look at the whole system at once, and that an undocumented fix counts as no fix. Build these deliberately and the US market becomes a durable growth channel rather than a detention risk. If you would like a second set of expert eyes on your export plan, get in touch with our team.